SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending following its recent earnings report, where the company exceeded revenue and EPS expectations, yet the stock experienced a notable after-hours decline. This unexpected dip, despite positive top and bottom-line results, has fueled community discussions ranging from claims of market manipulation to strong conviction among long-term investors buying the dip. Investors are actively debating the implications of the company's guidance, including its Q1 EPS forecast and projected doubling of ad revenue, alongside ongoing discussions about the strategic acquisition of Warner Bros. Discovery assets.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as community discussion surges following CEO Ryan Cohen's significant additional share purchases, fueling speculation that the stock's bottom is in and a new 'meme season' could be on the horizon. Investors are actively debating a potential short squeeze and eagerly awaiting any communication from "Roaring Kitty," while noting the stock's notable resilience amidst broader market weakness.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is actively trending following compelling Phase 1 clinical trial data for its oral drug soquelitinib in atopic dermatitis, which demonstrated strong efficacy and a favorable safety profile, driving the stock to significant gains. Community discussion highlights both excitement for its potential as a best-in-class treatment for a large market and concerns surrounding a recently announced stock offering, with opinions split on whether it's a strategic funding move or a precursor to dilution. Investors are keenly watching the long-term implications of this early-stage therapeutic and its market validation.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as the market reacts to escalating geopolitical tensions stemming from President Trump's aggressive rhetoric regarding Greenland and proposed tariffs on European allies. Community discussions reflect widespread anxiety over potential economic instability and a significant market sell-off, with many anticipating continued downside amid concerns about international relations and a carry trade unwind.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is attracting significant attention due to a highly positive FDA update for its ANKTIVA bladder cancer treatment, as the agency will not require new clinical trials for its resubmission, greatly de-risking the approval pathway. This development, combined with high short interest and massive trading volume, is driving strong community conviction around a potential short squeeze and the therapy's broader "cure for cancer" implications across multiple indications, even as the stock demonstrates notable resilience in a challenging market.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding Ltd. (TWG) is trending due to its announced acquisition of a $125 million wine authentication and trading business, aimed at diversifying its luxury product portfolio beyond caviar. This news initially propelled the stock with massive percentage gains, but the community is now sharply divided, with many expressing frustration over a significant price drop, attributing it to substantial share dilution from the acquisition and a recent public offering. Investors are actively debating whether it's a "pump and dump" or if further upside remains given its volatile, low-float nature.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid an intensifying bidding war, as Netflix recently revised its acquisition offer to all-cash for its studio and streaming assets. This move aims to counter Paramount Skydance's rival all-cash bid, though WBD's board continues to favor Netflix's proposal, citing concerns over Paramount's financing and the complexities of a potential breakup, leaving shareholders debating the superior path forward.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as renewed trade war concerns escalate following President Trump's rhetoric on Greenland and potential tariffs, fueling market uncertainty. Community sentiment is sharply divided between investors buying the dip and anticipating a swift rebound, and those bracing for a deeper correction. This geopolitical tension is broadly impacting sentiment around tech and AI-linked stocks, which are sensitive to risk-off moves.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending amid news of new contracts with the U.S. Army for AI-driven logistics and the Department of Health and Human Services to establish a unified national health-data platform. This recent federal traction, combined with a deepened Microsoft partnership and high short interest, is driving intense debate between those anticipating a major turnaround and skeptics pointing to persistent revenue challenges and insider selling.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending due to its planned split into two independent companies by 2026 and recent analyst downgrades, sparking an intense community debate. Many investors view the stock as deeply undervalued with an attractive dividend yield, believing current prices present a significant buying opportunity amidst accusations of market manipulation. The community largely anticipates value creation from the corporate separation, positioning KHC as a defensive play during broader market uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MediciNova (NASDAQ:MNOV) Share Price Crosses Above 200 Day Moving Average - Should You Sell?

MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving Average - Time to Sell...

MediciNova (NASDAQ:MNOV) Rating Increased to Strong-Buy at Lucid Cap Mkts

Lucid Cap Mkts upgraded shares of MediciNova to a "strong-buy" rating in a research note on Monday...

MediciNova (NASDAQ:MNOV) Shares Cross Above Two Hundred Day Moving Average - What's Next?

MediciNova (NASDAQ:MNOV) Share Price Crosses Above 200-Day Moving Average - Time to Sell...

MediciNova, Inc. (NASDAQ:MNOV) Sees Large Decline in Short Interest

MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) was the target of a significant decline in short interest in December. As of December 15th, there was short interest totaling 282,769 shares, a...

MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average - Should You Sell?

MediciNova (NASDAQ:MNOV) Shares Cross Above Two Hundred Day Moving Average - Here's Why...

MediciNova (NASDAQ:MNOV) Stock Price Passes Above Two Hundred Day Moving Average - Here's Why

MediciNova (NASDAQ:MNOV) Shares Pass Above 200 Day Moving Average - Here's What Happened...

MediciNova (NASDAQ:MNOV) Issues Earnings Results, Beats Estimates By $0.02 EPS

MediciNova (NASDAQ:MNOV - Get Free Report) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus...

<ul class="summary-bullets"><li>The newly published study showed that MediciNova’s compound tipelukast (MN-001) and its metabolite MN-002 helped the body clear cholesterol more effectively, a mechanism that could play a role in preventing artery plaque buildup.</li><li>The company said the findings build on earlier data from patients with fatty liver disease and high triglycerides, strengthening the case for the drug’s potential in metabolic and cardiovascular conditions.</li><li>On Stocktwits, retail traders described the after-hours move as a “monster” and said they were watching for a breakout above $2.50 with a “big green candle” in the next session.</li></ul>Shares of MediciNova Inc. jumped 85% in after-hours trading on Thursday after the biotechnology company said new research showed its experimental compound tipelukast (MN-001) and its metabolite MN-002 could offer a new therapeutic approach for atherosclerosis.The study, published in the Journal of Atherosclerosis and Thrombosis, found that MN-002 enhanced the body’s ability to remove cholesterol from immune cells by increasing the activity of transport proteins ABCA1 and ABCG1. The mechanism could help limit cholesterol buildup in arteries, a key factor in the development of cardiovascular disease.The research was conducted in collaboration with a Japanese academic group specializing in lipid and cholesterol metabolism. According to MediciNova, the findings suggest tipelukast may play a role in regulating cholesterol and lipid pathways, with potential applications in atherosclerosis, type 2 diabetes, and dyslipidemia.<h2 class="st-heading-2">Building On Earlier Clinical Results</h2>MediciNova said the findings add to previous clinical data showing improvements in cholesterol and triglyceride levels among patients with non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, particularly in those with diabetes.The company is nearing completion of enrollment for a Phase 2 randomized, double-blind, placebo-controlled study evaluating MN-001 in patients with hypertriglyceridemia, type 2 diabetes, and NAFLD.<h2 class="st-heading-2">Stocktwits Traders See Momentum Building</h2>On Stocktwits, retail sentiment for MediciNova was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:970/141;" src="https://news.stocktwits-cdn.com/mnov_ss_jpg_c4730fcad3.webp" alt="mnov ss.jpg" width="970" height="141"><figcaption>MNOV sentiment and message volume as of October 30 | Source: Stocktwits</figcaption></figure>One user described the move as a “monster” and said they were adding a small position in case the stock climbed further before the market opened.&nbsp;<stembedurl>https://stocktwits.com/makedatbread88/message/634417869</stembedurl>Another user noted that the next key level to watch was $2.50, adding that they were hoping to see a “big green candle” in the next session.<stembedurl>https://stocktwits.com/Targeted_Trading/message/634416145</stembedurl><a href="https://stocktwits.com/symbol/MNOV">MediciNova’s stock</a> has declined 43% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MediciNova’s stock (MNOV) has declined 43% so far in 2025. (Photo credit: Getty Images)

MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’ 

The newly published study showed that MediciNova’s compound tipelukast (MN-001) and its metabolite MN-002 helped the body clear cholesterol more effectively, a mechanism that could play a role in preventing artery plaque buildup.

Equity

&nbsp;The stock market rally stalled on Tuesday, with the S&amp;P 500 Index retreating from its record closing high of 6,001.35. The weakness could be due to traders taking profit off their recent gains and shifting to the sidelines ahead of some key Main Street data on inflation and retail sales.IT, real-estate and industrial stocks served as drags, while the strength in the consumer discretionary and financial spaces offset some of the weakness.As the market pauses, here’s a compilation of stocks retailers on the Stocktwits platform are most bullish and bearish about:Most BullishNeuronetics, Inc. ($STIM)Pennsylvania-based Neuronetics, a commercial-stage med-tech company has seen its shares plunge hard following its third-quarter earnings announcement. The loss per share of $0.44 grossly missed the consensus loss estimate of $0.23, and revenue of $18.53 million also trailed the $19.14 million.The stock plunged about 40% but retail is ‘extremely” bullish on the stock.Zscaler, Inc. ($ZS)Shares of Zscaler, a San Jose, California-based cybersecurity company, rose nearly 3% on&nbsp;Tuesday following an announcement regarding its “Zero Trust Segmentation” solution.&nbsp;This solution will “provide a more secure, agile and cost-effective means to connect users, devices, and workloads across and within globally distributed branches, factories, campuses, data centers, and public clouds,” the company said.Axsome Therapeutics, Inc. ($AXSM)New York-based Axsome, which focuses on central nervous system disorders, reported a double beat for the third quarter. The stock rose over 6% following the quarterly results. The company has an FDA decision date in late January for its migraine treatment candidate.&nbsp;“We expect a busy end to the year with several clinical catalysts anticipated, including a planned simultaneous release of topline results from the ongoing Phase 3 ADVANCE-2 and ACCORD-2 trials of AXS-05 in Alzheimer’s disease agitation in the fourth quarter,” said CEO Herriot Tabuteau.Bitcoin Depot, Inc. ($BTM)Atlanta, Georgia-based Bitcoin Depot provides users with simple and efficient ways to convert cash into Bitcoin ($BTC.X).&nbsp;The company’s shares are pulling back after Monday’s 54% jump but retail held on to its bullish bias.MediciNova, Inc. ($MNOV)La Jolla, California-based MediciNova, said it was notified by Sanofi ($SNY) that the Sanofi/Novartis AG ($NVS) litigation was settled. This provides for MediciNova receiving&nbsp;a certain amount of monetary damages through this settlement. MediciNova’s stock jumped following the news, triggering positive reaction from the retail crowd.Most BearishReviva Pharmaceuticals, Holdings, Inc. ($RVPH)Reviva, a late-stage&nbsp;pharma developing therapies in the areas of central nervous system, inflammatory and cardiometabolic diseases, announced a positive update on the enrollment for the ongoing 1-year open-label extension study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia. The stock climbed about 33% on Tuesday but retail sentiment was at a rock bottom.Pagaya Technologies Ltd. ($PGY)Israel-based Pagaya, a provider of&nbsp;financial products and services, reported a loss for the third quarter, which was much wider than expected. The stock slumped over 35%. Some among the retailers called outt the company a “fraud.Aldeyra Therapeutics, Inc. ($ALDX)Lexington, Massachusetts-based Aldeyra is a biotech focusing on therapies for immune-mediated and metabolic diseases. The shares of the company plunged on Tuesday on just about average volume.&nbsp;Retailers on the Stocktwits platform fretted over poor data for its dry eye disease product candidate.&nbsp;Quantum-Si Inc. ($QSI)Protein sequencing company Quantum-Si’s shares plunged over 22% on Tuesday after the&nbsp; Branford, Connecticut-based company reported its third-quarter results.ViaSat, Inc. ($VSAT)Shares of Carlsbad, California-based ViaSat have been ailing ever since the satellite telecommunications reported its financial results for the fiscal year 2025 second-quarter results last Thursday. This, in turn, has dented retail sentiment.&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/euphoric-run-of-tesla-stock-catalyzed-by-election-result-stalled/cJ40dh1ROF">Tesla Stock’s Post-Election Rally Stalls But Analyst Talks Up His $500 Bull-Case Scenario: Retail Mood Stays Sou</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

A slew of biopharma stocks made big moves on Tuesday. 

10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday

Earnings largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.

MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Medicinova Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.09	--	--	N/A
Q3 '25	-$0.12	-$0.12	--	EXPECTED
Q2 '25	-$0.09	-$0.12	-28.74%	MISSED
Q1 '25	-$0.14	-$0.06	57.14%	BEAT
Q4 '24	-$0.05	--	--	N/A

MNOV
Medicinova Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest MNOV News

MNOVMedicinova Inc